NCT00379041 is a Phase 3 clinical trial of bleomycin sulfate in Lymphoma, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

Who is sponsoring NCT00379041?

NCT00379041 is sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

What drugs are being tested in NCT00379041?

Interventions in NCT00379041: bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate, radiation therapy.

Is NCT00379041 still recruiting?

NCT00379041 is currently active, enrolled. Last updated 5 August 2025.

Last reviewed 2025-08-05 · How we verify

NCT00379041

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Active, enrolled Phase 3 Last updated 5 August 2025

What this trial tests

Phase 3 trial testing bleomycin sulfate in Lymphoma in 1,158 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 September 1993

Primary endpoint
1 October 1998

Quick facts

Lead sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Primary purpose	treatment
Enrollment	1,158
Start date	1 September 1993
Primary completion	1 October 1998

Drugs / interventions tested

bleomycin sulfate — full drug profile →
doxorubicin hydrochloride — full drug profile →
mechlorethamine hydrochloride
prednisone (prednisone) — full drug profile →
procarbazine hydrochloride
vinblastine sulfate
vincristine sulfate (Vincristine Sulfate) — full drug profile →
radiation therapy

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC — full company profile →

Who can join

Adults 15 to 70, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with combination chemotherapy may kill more cancer cells. It is not yet known whether radiation therapy is more effective with or without combination chemotherapy in treating patients with Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works with or without combination chemotherapy in treating patients with previously untreated stage I or stage II Hodgkin's lymphoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C, Eghbali H, Meerwaldt JH, Rieux C, et al · · 2007 · cited 265× · PMID 17989384 · DOI 10.1056/nejmoa064601
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, et al · · 2012 · cited 246× · PMID 22149921 · DOI 10.1056/nejmoa1111961
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
Heutte N, Flechtner HH, Mounier N, Mellink WA, et al · · 2009 · cited 65× · PMID 19828373 · DOI 10.1016/s1470-2045(09)70258-x

Verify or expand the search:

Other trials of bleomycin sulfate

Trials testing the same drug.

NCT01026220 — Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma · Phase 3 · completed
NCT00678327 — Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Sta · Phase 3 · completed
NCT00104676 — Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors · Phase 3 · completed
NCT00053352 — Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors · Phase 3 · completed
NCT00002565 — Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma · Phase 3 · completed

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other European Organisation for Research and Treatment of Cancer - EORTC trials

Trials by the same sponsor.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT06978062 — Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment · Phase 1 · not yet recruiting
NCT06809322 — Vorasidenib Maintenance for IDH Mutant Astrocytoma · Phase 3 · recruiting
NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
NCT06783348 — Radiopharmaceutical Treatment of Advanced Kidney Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00379041 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Organisation for Research and Treatment of Cancer - EORTC
Last refreshed: 5 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00379041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing